Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06445439

Optimal Pacing Rate for Cardiac Resynchronization Therapy

This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

Cardiac resynchronization therapy (CRT) after atrioventricular node (AVN) ablation for permanent atrial fibrillation (AF) has led to better outcomes in heart failure (HF) patients with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) compared to pharmacotherapy. Emerging evidence has demonstrated patients with HFpEF may benefit from a higher heart rate compared to standard heart-lowering therapies. The optimal pacing rate for CRT after AVN ablation in persistent AF and HFpEF remains unknown.

This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test.

The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa. Patient mortality and HF hospitalizations will be recorded at each phase. An electrocardiogram, echocardiogram, pacemaker interrogation, BNP and creatinine levels, KCCQ-12, six-minute walk test, and physical activity measure will be obtained at baseline, 3 months, and 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • History of persistent or permanent atrial fibrillation
  • Implantation of CRT or conduction system pacing in prior 3 months to 5 years of study start
  • History of intrinsic AVN block or have undergone AVN ablation in prior 3 months to 5 years of study start
  • LVEF ≥ 50%
  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) >400 pg/mL in the last 24 months
  • Clinical HF diagnosis or NYHA class II or higher
  • Able to provide informed consent

Exclusion criteria

  • LVEF <50%
  • Wide QRS (greater than 150ms)
  • Isolated RV pacing
  • Severe valvular disease
  • Severe coronary artery disease as defined by one of the following:
  • ACS or PCI within 1 year
  • Any angina (CCS class 1+)
  • Unrevascularizable severe CAD (>70% stenosis in 1+ major vessels and/or based on functional assessment)
  • ESRD
  • Significant primary pulmonary disease on home oxygen
  • Major orthopedic issues, such as being wheelchair bound and/or unable to perform a six-minute walk test
  • Ventricular ectopy >15% premature ventricular contractions (PVC)
  • End stage cancer diagnosis
  • Life expectancy less than one year
  • Palliative or hospice care
  • Hypertrophic cardiomyopathy (HCM)
  • Uncorrected ventricular septal defect
  • Infiltrative cardiomyopathy (CM)
  • Uncontrolled hypertension as defined by blood pressure >160/100 mm Hg on two measurements ≥15 minutes apart
  • Hemoglobin <7 g/dL
  • Age >90 years old
  • Pregnant or intends to become pregnant

Treatment and study plan

Pacing rate of 80 bpm

Device

Pacing rate of 80 bpm

Pacing rate of 60 bpm

Device

Pacing rate of 60 bpm

Primary outcomes

  1. Exercise tolerance as measured by the Six-Minute Walk Test

    Time frame: 3 months

    Exercise tolerance as measured by the Six-Minute Walk Test

Secondary outcomes

  1. Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire

    Time frame: 3 months

    Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire

  2. Function as measured by the International Physical Activity Questionnaire

    Time frame: 3 months

    Function as measured by the International Physical Activity Questionnaire

  3. Change in B-type natriuretic peptide (BNP)

    Time frame: 3 months

    Change in B-type natriuretic peptide (BNP)

  4. Change in creatinine

    Time frame: 3 months

    Change in creatinine

  5. Change in New York Heart Association Class

    Time frame: 3 months

    Change in New York Heart Association Class

  6. Atrial fibrillation burden

    Time frame: 3 months

    Atrial fibrillation burden as measured by pacemaker

  7. Hospitalization for heart failure

    Time frame: 3 months

    Hospitalization for heart failure

  8. Death due to heart failure

    Time frame: 3 months

    Death due to heart failure

  9. Death due to myocardial infarction

    Time frame: 3 months

    Death due to myocardial infarction

  10. Death due to stroke

    Time frame: 3 months

    Death due to stroke

  11. Hospitalization for atrial fibrillation

    Time frame: 3 months

    Hospitalization for atrial fibrillation

  12. Administration of loop diuretic/anti-arrhythmic drug

    Time frame: 3 months

    Administration of loop diuretic/anti-arrhythmic drug

Study contacts

Contact information is provided by the study sponsor or research team.

Sarahfaye Dolman

CONTACT

[email protected]

302-530-1873

Sponsors and collaborators

Lead sponsor

Medstar Health Research Institute

Other

Collaborators

  • Medtronic

Registry information

Official study title

Optimal Pacing Rate for Cardiac Resynchronization Therapy After Atrioventricular Node Ablation in Persistent Atrial Fibrillation and Heart Failure

Acronym: OPT-RATE AF

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 6, 2024
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.